Product Information
DIOVAN HCT 160-25 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $13.0470 per EA under NDC 00078038334. Its NADAC has been published 283 times since Nov 28, 2013.
FDA first approved this application on Mar 6, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the valsartan and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25; 160 mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078038334
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/7/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA020818FDA Approved
3/6/1998
TE Code
AB
On Market Since
3/6/1998
Pharmacological Classes
Price Statistics
The NADAC for DIOVAN HCT 160-25 MG TABLET has been published 283 times since Nov 28, 2013, and over the history we have for it it has risen 171.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.0470 per EA |
|---|---|
| All-time high | $13.0470 (Mar 11, 2026) |
| All-time low | $4.8108 (Nov 28, 2013) |
| 52-week high | $13.0470 |
| 52-week low | $12.6670 |
| Median price | $7.6578 |
| Average price | $8.6192 |
| Largest weekly change | +48.3% (Aug 21, 2024) |
| Weeks tracked | 283 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
+3.0%
3Y
+56.2%
5Y
+56.2%
All
+171.2%
Last surveyed Mar 11, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
valsartan and hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DIOVAN HCT 160-25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DIOVAN HCT 160-25 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $13.0470 per EA (NDC 00078038334), effective Mar 11, 2026.
How has the price of DIOVAN HCT 160-25 MG TABLET changed over time?
Over the history we have for it, the NADAC for DIOVAN HCT 160-25 MG TABLET has risen 171.2%. It has been tracked across 283 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DIOVAN HCT 160-25 MG TABLET?
Since Nov 28, 2013, the NADAC for DIOVAN HCT 160-25 MG TABLET has ranged from a low of $4.8108 (Nov 28, 2013) to a high of $13.0470 (Mar 11, 2026), with a median of $7.6578 per EA.
Are there cheaper alternatives to DIOVAN HCT 160-25 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VALSARTAN-HYDROCHLOROTHIAZIDE 160-25 MG TAB, is $0.1214 per EA — about 99% below DIOVAN HCT 160-25 MG TABLET.
Who manufactures DIOVAN HCT 160-25 MG TABLET?
DIOVAN HCT 160-25 MG TABLET (NDC 00078038334) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.